CD73 blocking agents
US11130817B2 · kind B2 · utility
2Cited by
0References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 11, 2016 |
| Grant date | Sep 28, 2021 |
| Priority date | — |
| Expiry date | Dec 27, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Provided are antibodies that bind and inhibit CD73, are capable of increasing the proliferation of T cells in the presence of CD39-expressing B cells and ATP. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.